MAPT and Alzheimer disease: Application of these techniques to CSF or more accessible samples from patients to provide accurate intra-vitam biochemical confirmation of tauopathy diagnosis, and quantification of seeding activity, requires further work, but would be important since tauopathies underlie some of the most common neurodegenerative disorders including AD and tau is a promising drug target for clinical trials.